In the last week, the market has stayed flat, but it is up 26% over the past year with earnings expected to grow by 17% per annum over the next few years. The term 'penny stocks' might feel like a relic of past market eras, but they continue to offer potential for growth when backed by strong financials and solid fundamentals. In this article, we explore several penny stocks that stand out for their financial strength and could represent promising opportunities in today's evolving market landscape.

Let's dive into some prime choices out of the screener.

Stabilis Solutions (SLNG)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Stabilis Solutions, Inc. is an energy transition company offering turnkey clean energy solutions with a focus on liquefied natural gas (LNG) across North America, with a market cap of $70.50 million.

Operations: The company's revenue is primarily derived from its Oil & Gas - Refining & Marketing segment, which generated $61.29 million.

Market Cap: $70.5M

Stabilis Solutions, Inc., with a market cap of US$70.50 million, focuses on LNG solutions and faces challenges typical of penny stocks. The company remains unprofitable but has managed to reduce losses over the past five years. Despite having sufficient cash runway for over three years due to positive free cash flow growth, its recent earnings report showed a decline in sales to US$10.38 million and an increased net loss of US$4.08 million for Q1 2026 compared to the previous year. The company's stock is highly volatile, yet shareholders have not faced significant dilution recently.

E.W. Scripps (SSP)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: The E.W. Scripps Company operates as a media enterprise in the United States, managing a portfolio of local television stations and national news and entertainment networks, with a market cap of approximately $314.90 million.

Operations: The company's revenue is primarily generated from its Local Media segment, which accounts for $1.36 billion, and its Scripps Networks segment, contributing $782.24 million.

Market Cap: $314.9M

E.W. Scripps, with a market cap of US$314.90 million, is navigating the challenges of being unprofitable while maintaining a strong presence in media through strategic partnerships and financial maneuvers. Recent agreements, such as the local broadcast deal with the Detroit Pistons and expansion into women's rodeo programming, bolster its media footprint. Despite reporting a net loss of US$1.79 million for Q1 2026, Scripps has extended its credit facility to ensure liquidity until 2029. The company benefits from experienced management and board teams but faces high debt levels and long-term liabilities exceeding short-term assets by over US$2 billion.

Liquidmetal Technologies (LQMT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Liquidmetal Technologies, Inc. is a materials technology company that designs, develops, and sells custom products and parts made from bulk amorphous alloys to various industries globally, with a market cap of $134.84 million.

Operations: Liquidmetal Technologies has not reported any specific revenue segments.

Market Cap: $134.84M

Liquidmetal Technologies, with a market cap of US$134.84 million, operates in the materials technology sector and is currently pre-revenue, reporting only US$0.784 million in revenue for 2025. The company has managed to reduce its losses over the past five years at an annual rate of 10.8%, despite remaining unprofitable with a net loss of US$2.34 million last year. Liquidmetal is debt-free and benefits from a strong cash position, with short-term assets significantly exceeding both short-term and long-term liabilities—providing it with more than three years of cash runway based on current free cash flow trends.

Make It Happen

• Unlock more gems! Our US Penny Stocks screener has unearthed 334 more companies for you to explore.Click here to unveil our expertly curated list of 337 US Penny Stocks.
• Looking For Alternative Opportunities? AI is about to change healthcare. These 131 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.